Compare Gilead Sciences, Inc. (GILD) vs HP Inc (HPQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs HP Inc — how do they compare? Gilead Sciences, Inc. trades at $137.04 (market cap $168.35B), while HP Inc trades at $28.61 (market cap $26.59B). The key difference: Gilead Sciences, Inc. is far larger — about 6.3× HP Inc's market cap, and HP Inc pays the higher dividend (4.13%). Which is the better fit depends on your goals.
| GILD | HPQ | |
|---|---|---|
Market Cap | $168.35B | $26.59B |
Sector | Health | Technology |
52-Week High | $155.80 | $30.05 |
52-Week Low | $110.56 | $18.20 |
Enterprise Value | $191.42B | $33.75B |
Dividend Yield | 2.42% | 4.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
HPQ trades at $29.80, down 0.83% on the day, with a bullish technical signal supported by moving averages and positive earnings beats in recent quarters. The company reported Q2 2026 revenue of $14.4B and EPS of $0.86, exceeding expectations, driven by premium product mix and AI-driven efficiencies. Valuation metrics show a P/E of 10.77 and P/S of 0.48, indicating potential undervaluation relative to historical averages.
The outlook remains positive with continued earnings momentum and a 2026 revenue forecast of $57.4B, though risks include PC market volatility and competitive pressures. Analyst consensus is mixed with 29% buy ratings, but technical support at $29 suggests near-term stability. The dividend yield of approximately 4% provides income appeal amid growth initiatives.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →
